METAGENOMI THERAPEUTICS INC (MGX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:MGX • US59102M1045

1.45 USD
-0.04 (-2.68%)
At close: Feb 4, 2026
1.47 USD
+0.02 (+1.38%)
After Hours: 2/4/2026, 4:30:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MGX. MGX was compared to 524 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MGX as it has an excellent financial health rating, but there are worries on the profitability. MGX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • MGX had negative earnings in the past year.
  • In the past year MGX has reported a negative cash flow from operations.
MGX Yearly Net Income VS EBIT VS OCF VS FCFMGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

  • With a decent Return On Assets value of -35.79%, MGX is doing good in the industry, outperforming 61.83% of the companies in the same industry.
  • MGX's Return On Equity of -49.73% is fine compared to the rest of the industry. MGX outperforms 66.41% of its industry peers.
Industry RankSector Rank
ROA -35.79%
ROE -49.73%
ROIC N/A
ROA(3y)-17.76%
ROA(5y)N/A
ROE(3y)-27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MGX Yearly ROA, ROE, ROICMGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MGX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MGX Yearly Profit, Operating, Gross MarginsMGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

  • MGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MGX has less shares outstanding than it did 1 year ago.
  • MGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MGX Yearly Shares OutstandingMGX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
MGX Yearly Total Debt VS Total AssetsMGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -1.47, we must say that MGX is in the distress zone and has some risk of bankruptcy.
  • MGX has a Altman-Z score (-1.47) which is comparable to the rest of the industry.
  • There is no outstanding debt for MGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.47
ROIC/WACCN/A
WACC8.92%
MGX Yearly LT Debt VS Equity VS FCFMGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • MGX has a Current Ratio of 6.42. This indicates that MGX is financially healthy and has no problem in meeting its short term obligations.
  • MGX has a better Current ratio (6.42) than 65.46% of its industry peers.
  • MGX has a Quick Ratio of 6.42. This indicates that MGX is financially healthy and has no problem in meeting its short term obligations.
  • MGX's Quick ratio of 6.42 is fine compared to the rest of the industry. MGX outperforms 66.41% of its industry peers.
Industry RankSector Rank
Current Ratio 6.42
Quick Ratio 6.42
MGX Yearly Current Assets VS Current LiabilitesMGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 4.15% over the past year.
  • The Revenue for MGX has decreased by -43.88% in the past year. This is quite bad
  • MGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 499.26% yearly.
EPS 1Y (TTM)4.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.84%
Revenue 1Y (TTM)-43.88%
Revenue growth 3Y499.26%
Revenue growth 5YN/A
Sales Q2Q%-24.8%

3.2 Future

  • MGX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.87% yearly.
  • MGX is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -28.04% yearly.
EPS Next Y9.05%
EPS Next 2Y13.95%
EPS Next 3Y11.39%
EPS Next 5Y7.87%
Revenue Next Year-46.01%
Revenue Next 2Y-34.84%
Revenue Next 3Y-22.7%
Revenue Next 5Y-28.04%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MGX Yearly Revenue VS EstimatesMGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
MGX Yearly EPS VS EstimatesMGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • MGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MGX Price Earnings VS Forward Price EarningsMGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGX Per share dataMGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.95%
EPS Next 3Y11.39%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for MGX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

METAGENOMI THERAPEUTICS INC

NASDAQ:MGX (2/4/2026, 4:30:01 PM)

After market: 1.47 +0.02 (+1.38%)

1.45

-0.04 (-2.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11
Earnings (Next)03-11
Inst Owners17.78%
Inst Owner Change-6.4%
Ins Owners9.75%
Ins Owner Change4.4%
Market Cap54.42M
Revenue(TTM)30.91M
Net Income(TTM)-88.74M
Analysts80
Price Target9.52 (556.55%)
Short Float %8.89%
Short Ratio7.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.33%
Min EPS beat(2)6.75%
Max EPS beat(2)13.9%
EPS beat(4)3
Avg EPS beat(4)5.25%
Min EPS beat(4)-16.48%
Max EPS beat(4)16.83%
EPS beat(8)6
Avg EPS beat(8)16.91%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)12.52%
Min Revenue beat(2)9.18%
Max Revenue beat(2)15.86%
Revenue beat(4)3
Avg Revenue beat(4)-3.61%
Min Revenue beat(4)-48.67%
Max Revenue beat(4)15.86%
Revenue beat(8)7
Avg Revenue beat(8)20.5%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.43%
EPS NY rev (1m)0%
EPS NY rev (3m)1.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.16%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.76
P/FCF N/A
P/OCF N/A
P/B 0.3
P/tB 0.3
EV/EBITDA N/A
EPS(TTM)-2.4
EYN/A
EPS(NY)-1.84
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.44
OCFYN/A
SpS0.82
BVpS4.75
TBVpS4.75
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.79%
ROE -49.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-17.76%
ROA(5y)N/A
ROE(3y)-27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.02%
Cap/Sales 2.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.42
Quick Ratio 6.42
Altman-Z -1.47
F-Score2
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)365.8%
Cap/Depr(5y)N/A
Cap/Sales(3y)36.38%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.84%
EPS Next Y9.05%
EPS Next 2Y13.95%
EPS Next 3Y11.39%
EPS Next 5Y7.87%
Revenue 1Y (TTM)-43.88%
Revenue growth 3Y499.26%
Revenue growth 5YN/A
Sales Q2Q%-24.8%
Revenue Next Year-46.01%
Revenue Next 2Y-34.84%
Revenue Next 3Y-22.7%
Revenue Next 5Y-28.04%
EBIT growth 1Y-4.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.41%
EBIT Next 3Y-14.71%
EBIT Next 5YN/A
FCF growth 1Y-10.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.32%
OCF growth 3YN/A
OCF growth 5YN/A

METAGENOMI THERAPEUTICS INC / MGX FAQ

Can you provide the ChartMill fundamental rating for METAGENOMI THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to MGX.


What is the valuation status of METAGENOMI THERAPEUTICS INC (MGX) stock?

ChartMill assigns a valuation rating of 0 / 10 to METAGENOMI THERAPEUTICS INC (MGX). This can be considered as Overvalued.


What is the profitability of MGX stock?

METAGENOMI THERAPEUTICS INC (MGX) has a profitability rating of 1 / 10.


Can you provide the financial health for MGX stock?

The financial health rating of METAGENOMI THERAPEUTICS INC (MGX) is 7 / 10.